- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05871918
A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer
A Multicenter, Randomized, Open, Phase III Trial of ddEC-THP(Epirubicin,Cyclophosphamide,TAX(Taxol),Trastuzumab,Pertuzumab)vs Evaluating the Efficacy and Safety of TCHP (CBP(Carboplatin),TXT(Taxotere),Trastuzumab,Pertuzumab)Neoadjuvant Therapy for HER2-positive Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Zhongsheng Tong
- Phone Number: +8618622221181
- Email: 18622221181@163.com
Study Contact Backup
- Name: Lin Gu
- Phone Number: +8613011309052
- Email: gulindr@126.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Recruiting
- Breast Oncology, Tianjin Medical University Cancer Institute and Hospital
-
Contact:
- Zhongsheng Tong, MD
- Phone Number: +8618622221181
- Email: 18622221181@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 18 ~70 years old, female;
- Histologically confirmed patients with previously untreated stage Ⅱ-Ⅲ HER2-positive breast cancer;
- HER-2 positive breast cancer, defined as immunohistochemical (IHC) detection of 3+ or in situ hybridization (FISH) results of HER2 gene amplification;
- There is at least one measurable objective lesion according to RECIST 1.1 criteria;
- ECOG Physical fitness score is 0-2;
- Left ventricular ejection fraction LVEF≥50%;
- Bone marrow function: neutrophils ≥1.5×109/L, platelets ≥100×109/L, hemoglobin ≥90g/L;
- Liver and kidney function: serum creatinine ≤1.5 times the upper limit of normal value; AST and ALT≤2.5 times the upper limit of normal, or ≤5 times the upper limit of normal in the presence of liver metastasis; Total bilirubin ≤1.5 times the upper limit of normal, or ≤2.5 times the upper limit of normal in patients with Gilbert's syndrome, creatinine clearance greater than 30 mL/min;
- For female patients who are not menopausal or have not been surgically sterilized: consent to abstinence or use an effective contraceptive method during treatment and for at least 7 months after the last dose in the study treatment
- The patient has good compliance with the planned treatment, can understand the research process of the study and sign the written informed consent.
Exclusion Criteria:
- Stage IV (metastatic) breast cancer patients;
- Patients with inflammatory breast cancer
Serious heart disease or discomfort, including but not limited to:
- History of heart failure or systolic dysfunction (LVEF < 50%)
- High-risk uncontrolled arrhythmias such as atrial tachycardia, resting heart rate > 100 bpm, significant ventricular arrhythmias (e.g., ventricular tachycardia) or higher-grade atrioventricular block (i.e., Mobitz II second-degree atrioventricular block or third-degree atrioventricular block) Angina pectoris that requires antiangina medication
- valvular heart disease of clinical significance
- ECG showed transmural myocardial infarction
- Poor hypertension control (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg)
- Known allergic history of drug components of this protocol; A history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
- Patients with severe systemic infection or accompanied by other serious diseases;
- Have developed other malignant tumors within the previous 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer;
- Pregnant and lactating women, fertile women who tested positive for baseline pregnancy tests, or patients of childbearing age who were unwilling to take effective contraceptive measures during the entire trial period and within 6 months after the last study;
- Patients who participated in other studies within 30 days prior to the first dose of the investigational drug;
- Patients deemed unsuitable for this study by the investigator.
- The patient has good compliance with the planned treatment, can understand the research process of the study and sign the written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TCbHP
Experimental group (TCbHP) : Taxotere (75mg/m2) + Carboplatin (AUC=5) Trastuzumab 6mg/kg(initial dose 8mg/kg) Pertuzumab 420mg(initial dose 840mg) 1/21d times 6 cycle |
The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles.
If treatment does not work, change the treatment plan according to the clinician's decision.
|
Placebo Comparator: ddEC-THP
Epirubicin (90mg/m2)+ cyclophosphamide (600mg/m2) 1/14d×4 cycle Taxol (80mg/m2) 1/7d x 12w Trastuzumab 6mg/kg(initial dose 8mg/kg) 1/21d ×4 cycles Pertuzumab 420mg(initial dose 840mg) 1/21d x 4 cycles |
The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles.
If treatment does not work, change the treatment plan according to the clinician's decision.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pCR rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery
Time Frame: Up to approximately 24 weeks
|
pCR rate (ypT0/is,ypN0) is defined as the percentage of participants without residual invasive tumor on hematoxylin and eosin evaluation of breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery in all participants.
|
Up to approximately 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event-Free Survival (EFS)
Time Frame: Up to approximately 3 years
|
EFS is defined as the time from start of study treatment to any of the following events: progression of disease that precludes surgery, local or distant recurrence, second primary malignancy (breast or other cancers) or death due to any cause.
|
Up to approximately 3 years
|
Invasive Disease-Free Survival (iDFS)
Time Frame: Up to approximately 3 years
|
iDFS events are defined as follows: (1)Ipsilateral invasive breast tumor recurrence.
(2) Ipsilateral local-regional invasive breast cancer recurrence.
(3) Ipsilateral second primary invasive breast cancer.
(4) Contralateral invasive breast cancer.
(5) Distant recurrence.
(6) Death attributable to any cause.
|
Up to approximately 3 years
|
Overall survival (OS)
Time Frame: Up to approximately 3 years
|
OS is defined as the time from randomization to death due to any cause.
Participants without documented death at the time of the analysis will be censored at the date of the last follow-up.
|
Up to approximately 3 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIH-TZS-20201008-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER-2 Positive Breast Cancer
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)RecruitingHER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of BreastUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedBreast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | HER-2 Gene Amplification | Breast Cancer Female | HER2 Positive Breast Carcinoma | HER-2 Protein OverexpressionUnited States
-
Orum Therapeutics USA, Inc.RecruitingHER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein OverexpressionUnited States
-
Alliance Foundation Trials, LLC.Pfizer; Syneos Health; UNICANCER; German Breast Group; SOLTI Breast Cancer Research... and other collaboratorsActive, not recruitingHER-2 Positive Breast Cancer | Estrogen Receptor Positive Breast CancerUnited States, Spain, France, Italy, Germany, Australia, Portugal, New Zealand
-
Eli Lilly and CompanyCompletedHER-2 Positive Breast Cancer | Hormone Receptor Positive Breast CancerSpain, United States, Korea, Republic of, Belgium, France, Germany, Italy, Australia, Argentina, Canada, United Kingdom, Mexico, Brazil, Greece
-
Texas Tech University Health Sciences Center, El...WithdrawnBreast Cancer | Metastatic Breast Cancer | HER-2 Positive Breast Cancer | ER Positive Breast Cancer
-
Zhimin ShaoRoche Pharma AGUnknownHER-2 Positive Breast CancerChina
-
Washington University School of MedicineMolecular Templates, Inc.WithdrawnHER2-positive Solid Tumor | HER-2 Positive Cancer
-
Hospices Civils de LyonNot yet recruiting
-
Adrienne G. WaksEli Lilly and Company; Verastem, Inc.RecruitingBreast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast CancerUnited States
Clinical Trials on TCbHP VS ddEC-THP
-
Shengjing HospitalRecruiting
-
Guangdong Provincial People's HospitalUnknownHER2-Positive Breast CancerChina
-
Henan Cancer HospitalWithdrawnBreast Cancer | HER2-positive Breast CancerChina